PBX1 identified as a new pioneer factor underlying progression in breast cancer

November 17, 2011

The presence of a new pioneer factor, known as PBX1, can guide the response to estrogen in breast cancer cells according to researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center in results published on November 17 in the open-access journal PLoS Genetics. This research reveals that PBX1 alone can determine the risk of the spread of cancer in patients with estrogen receptor alpha (ERα)-positive breast cancer, which accounts for about two-thirds of all breast cancers diagnosed in North America.

Pioneer factors are an emerging class of chromatin remodelers with the capacity to modulate cellular identity as they set the stage by defining the genomic regions accessible for transcription factors. "Since cancer is characterized by a loss of cell-fate identity, it is not surprising that other pioneer factors have already been characterized as oncogenic factors in breast cancer, but PBX1 is one that discriminates progression," said Dr. Mathieu Lupien, assistant professor of genetics, Norris Cotton Cancer Center, Dartmouth Medical School, who served as principal investigator for the study. Specifically, this research demonstrates that PBX1 directly modulates chromatin compaction at discrete genomic regions to promote the recruitment of the transcription factor ERα, driving the proliferative response to estrogen in .

"Unfortunately, numerous ERα-positive patients with breast cancer progress to more advanced stages of the disease as they develop resistance to endocrine therapies, which directly target ERα." said lead author Dr. Luca Magnani, post-doctoral scientist.

"This work may rapidly translate to the clinic because PBX1 could likely serve as a prognostic marker for ERα-positive breast cancer progression. It also highlights the potential therapeutic benefit of developing means to antagonize pioneer factors such as PBX1 to prevent progression" said Dr. Lupien.

Explore further: False negative tests in breast cancer may lead to wrong drug choice

More information: Magnani L, Ballantyne EB, Zhang X, Lupien M (2011) PBX1 Genomic Pioneer Function Drives ERa Signaling Underlying Progression in Breast Cancer. PLoS Genet 7(11): e1002368. doi:10.1371/journal.pgen.1002368

Related Stories

Elevated hormone levels add up to increased breast cancer risk

October 21, 2011

Post-menopausal women with high levels of hormones such as estrogen or testosterone are known to have a higher risk of breast cancer. New research published in BioMed Central's open access journal Breast Cancer Research looked ...

Recommended for you

Regulatory RNA essential to DNA damage response

September 26, 2016

Stanford researchers have found that a tumor suppressor known as p53 is stabilized by a regulatory RNA molecule called DINO. The interaction helps a cell respond to DNA damage and may play a role in cancer development and ...

Multifaceted genetic impact of training

September 23, 2016

Endurance training changes the activity of thousands of genes and give rise to a multitude of altered DNA-copies, RNA, researchers from Karolinska Institutet report. The study, which also nuances the concept of muscle memory, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.